Antiemetic adherence following pharmacist counseling and chemotherapy-induced nausea and vomiting across repeated chemotherapy cycles: A retrospective cohort study
Introduction Chemotherapy-induced nausea and vomiting (CINV) remains a clinically relevant adverse effect of antineoplastic treatment. This study evaluated the association between adherence to prescribed antiemetic therapy following pharmacist counseling and CINV across repeated chemotherapy cycles, while also characterizing longitudinal patterns and pharmacist interventions (PIs). Methods This retrospective cohort included adult patients treated at a tertiary university hospital in Southern Brazil between June 1, 2021, and June 1, 2022. Adherence and CINV were assessed from patient or caregiver reports. Associations between adherence and CINV were estimated using modified Poisson generalized estimating equations with robust variance, accounting for repeated cycles within patients and adjusting for age, sex, emetogenic potential, and cycle number. First-cycle sensitivity, consecutive-cycle longitudinal, and exploratory prescriber-directed PI analyses were also performed. Results Among 123 identified patients, 110 contributed 361 evaluable chemotherapy cycles. 199 (55.1%) were adherent. In the adjusted repeated-cycle analysis, adherence was associated with a lower risk of acute CINV (RR 0.65, 95% CI 0.43–0.98; p = 0.039), whereas associations with overall (RR 0.88, 95% CI 0.70–1.11; p = 0.288) and delayed CINV (RR 0.83, 95% CI 0.64–1.07; p = 0.149) were not statistically significant. The first-cycle sensitivity analysis showed lower risks of overall and acute CINV among adherent patients. Previous CINV was associated with recurrence in the subsequent cycle, particularly for acute CINV (RR 3.91, 95% CI 2.31–6.62; p < 0.001), while previous adherence strongly predicted adherence in the next cycle (RR 1.90, 95% CI 1.38–2.63; p < 0.001). Among 74 evaluable prescriber-directed PIs, CINV frequencies decreased numerically after intervention. Conclusion Adherence to prescribed antiemetic therapy following pharmacist counseling was associated with a lower risk of acute CINV. Adherence and CINV demonstrated longitudinal patterns, supporting repeated assessment of symptom control and medication use throughout treatment. These findings also support further evaluation of pharmacist-led strategies to promote antiemetic adherence and optimize CINV management.
Authors
- Inajara Rotta (ORCID: https://orcid.org/0000-0002-9099-7216)
- William Lucas Ferreira da Silva (ORCID: https://orcid.org/0000-0001-8012-9004)
- Antônio Matoso Mendes
- Vítor Henrique COSTA (ORCID: https://orcid.org/0000-0001-5851-2605)
Institutions
- Universidade Federal do Paraná (BR)
Publication Details
- Journal
- Journal of Oncology Pharmacy Practice
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1177/10781552261506215
- Primary Topic
- Nausea and vomiting management
- Type
- article
- Field-Weighted Citation Impact
- 0.00